BioCryst Pharmaceuticals
BCRX
$9.60
+9.09%
BioCryst Pharmaceuticals Inc is a biotechnology company focused on the research and development of novel small-molecule drugs designed to block key enzymes involved in infectious and inflammatory diseases, operating within the highly competitive and R&D-intensive biotech industry. The company has established itself as a commercial-stage player with a targeted focus on rare diseases, most notably hereditary angioedema (HAE), where its lead product, ORLADEYO (berotralstat), provides a distinct oral prophylactic treatment option in a market historically dominated by injectables. The current investor narrative is centered on the company's transition to a self-sustaining commercial entity, driven by ORLADEYO's revenue ramp and the critical path to achieving profitability, while debates persist regarding the long-term commercial potential against entrenched competitors and the company's ability to manage its significant debt load.…
BCRX
BioCryst Pharmaceuticals
$9.60
Investment Opinion: Should I buy BCRX Today?
Rating: Hold. The core thesis is that BCRX is a commercially viable but financially risky biotech in transition, where attractive profitability and momentum are counterbalanced by a weak balance sheet, making the risk/reward profile balanced at current levels.
Supporting evidence includes a trailing P/E of 6.20x that looks inexpensive, a forward P/E of 11.25x that embeds growth expectations, a stellar gross margin of 97.82%, and strong relative price momentum of +24.27% over three months. However, the negative debt-to-equity of -4.01 and lack of a clear analyst price target limit conviction on upside.
The thesis would upgrade to a Buy if the company demonstrates sustained quarter-over-quarter revenue growth in line with the ~$1.3B analyst estimate while improving its balance sheet metrics, or if the stock corrects meaningfully toward the $6.00 support level. It would downgrade to a Sell if revenue growth stalls, debt levels increase, or the stock breaks below its 52-week low. Relative to its own metrics, the stock appears fairly valued given the high growth expectations and high financial risk, trading at a discount on trailing earnings but a premium on forward expectations.
Sign up to view all
BCRX 12-Month Price Forecast
BCRX presents a balanced but uncertain 12-month outlook. The company's strong product economics (97.82% gross margin) and current profitability are clear positives, but they are overshadowed by a precarious balance sheet. The base case of steady execution is most probable, but the stock's path will be highly sensitive to quarterly revenue prints. The stance is neutral due to the offsetting forces of attractive fundamentals and high financial risk. An upgrade to bullish would require clear evidence of debt reduction or sustained revenue acceleration above estimates. A downgrade to bearish would be triggered by a growth slowdown or further deterioration in shareholder equity.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BioCryst Pharmaceuticals's 12-month outlook, with a consensus price target around $12.48 and implied upside of +30.0% versus the current price.
Average Target
$12.48
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$8 - $12
Analyst target range
Insufficient analyst coverage is available, with only three analysts providing estimates, which is minimal for a company of this market cap. This limited coverage typically indicates it is a smaller, more specialized biotech with constrained institutional interest, which can lead to higher volatility and less efficient price discovery as the stock reacts more sharply to company-specific news. The provided data includes revenue and EPS estimates but lacks a consensus price target, buy/hold/sell ratings, or a target price range, preventing any calculation of implied upside or analysis of analyst sentiment dispersion; the estimated revenue range of $1.25 billion to $1.35 billion and EPS range of $1.56 to $1.72 show some variability, signaling moderate uncertainty around the precise trajectory of the company's commercial execution and profitability.
Bulls vs Bears: BCRX Investment Factors
The evidence presents a classic biotech battleground stock, with the bull case anchored in strong current profitability, accelerating momentum, and a seemingly cheap trailing valuation. The bear case is fundamentally rooted in a precarious financial structure and skepticism about future earnings sustainability. Currently, the technical momentum and profitability metrics provide stronger near-term evidence for the bulls. The single most important tension in the investment debate is whether the company's high-margin revenue from ORLADEYO can grow rapidly and consistently enough to overcome its significant debt burden and negative equity, thereby validating the forward growth expectations embedded in its valuation.
Bullish
- Strong Profitability & Pricing Power: The company boasts a trailing net margin of 30.16% and an exceptional gross margin of 97.82%, indicating its lead product, ORLADEYO, has strong pricing power and low cost of goods sold. This provides a robust foundation for cash generation as sales scale.
- Accelerating Technical Momentum: BCRX has significantly outperformed the market, gaining 20.27% over the past three months versus the S&P 500's 4% decline, a relative strength of +24.27. The stock is trading at $9.02, well above its 52-week low of $6.00, signaling a strong recovery phase.
- Low Trailing Valuation Multiple: The stock trades at a trailing P/E of just 6.20x, which appears low for a commercial-stage biotech with high margins. This could indicate the market is undervaluing the company's current profitability, presenting a potential value opportunity.
- High Revenue Growth Expectations: Analysts project average revenue of approximately $1.30 billion, signaling strong confidence in the commercial ramp of ORLADEYO. The forward P/E of 11.25x, while higher than trailing, reflects expectations for continued growth and investment.
Bearish
- Deteriorated Capital Structure: The company has a deeply negative debt-to-equity ratio of -4.01 and a negative ROE of -221.45%, revealing a balance sheet burdened by debt and accumulated deficits. This financial structure heightens risk and underscores an urgent need for sustained positive cash flow.
- Limited Analyst Coverage & Sentiment: With only three analysts providing estimates, there is minimal institutional coverage, which can lead to higher volatility and less efficient price discovery. The lack of a consensus price target or rating further obscures the professional investment community's view.
- Forward Earnings Compression Risk: The forward P/E of 11.25x is substantially higher than the trailing P/E of 6.20x, implying the market expects a significant drop in near-term earnings per share. This gap suggests anticipated investments or costs that could pressure profitability before scaling benefits materialize.
- High Short Interest: A short ratio of 8.06 indicates a significant portion of the float is sold short, reflecting a skeptical or bearish view among some investors. This creates potential for near-term volatility, especially on any positive news that could trigger a short squeeze.
BCRX Technical Analysis
The stock is in a pronounced recovery phase, having surged 21.40% over the past year, and is currently trading at approximately 80% of its 52-week range (based on a recent close of $9.02 against a 52-week high of $11.31 and low of $6.00), indicating strong momentum but not yet at overextended highs. Recent momentum is exceptionally strong and accelerating, with the stock up 20.27% over the past three months and 3.80% over the past month, significantly outperforming the S&P 500 which declined 4.00% and 4.28% over the same periods, respectively, as evidenced by relative strength readings of +24.27 and +8.08. Key technical support is anchored at the 52-week low of $6.00, while immediate resistance lies at the 52-week high of $11.31; a sustained breakout above this level would signal a new bullish phase, while a breakdown below $6.00 would invalidate the recovery thesis. The stock's beta of 0.69 indicates it has been about 31% less volatile than the broader market, which is atypical for a biotech but may reflect its transition to a commercial story with more predictable revenue streams.
Beta
0.57
0.57x market volatility
Max Drawdown
-44.2%
Largest decline past year
52-Week Range
$6-$11
Price range past year
Annual Return
-4.6%
Cumulative gain past year
| Period | BCRX Return | S&P 500 |
|---|---|---|
| 1m | +2.0% | +8.2% |
| 3m | +41.2% | +9.0% |
| 6m | +35.6% | +10.5% |
| 1y | -4.6% | +26.5% |
| ytd | +28.0% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BCRX Fundamental Analysis
Revenue trajectory data is not available in the provided quarterly financials, but analyst estimates point to significant growth expectations with average projected revenue of approximately $1.30 billion, suggesting the market is pricing in a substantial commercial ramp for its lead product. The company is profitable on a trailing basis with a net margin of 30.16% and an impressive gross margin of 97.82%, indicating its product has strong pricing power and low cost of goods sold; however, a negative Return on Equity (ROE) of -221.45% signals significant accumulated deficits and shareholder dilution, which is common for commercial-stage biotechs with past heavy R&D spending. The balance sheet shows a current ratio of 2.06, suggesting adequate short-term liquidity, but a deeply negative debt-to-equity ratio of -4.01 reveals a capital structure burdened by debt and retained losses, underscoring the critical importance of generating sustained positive free cash flow, which is not detailed in the provided data, to service obligations and fund future operations.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BCRX Overvalued?
Given the positive trailing Net Income (implied by a positive net margin and trailing P/E), the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 6.20x and a forward P/E of 11.25x; the substantial gap between these multiples implies the market expects a significant drop in near-term earnings, which aligns with analyst EPS estimates that are materially higher than the trailing figure, suggesting anticipated investments may pressure profits before longer-term scaling. Peer comparison data for industry averages is not available in the provided valuation dataset, preventing a quantified premium/discount analysis; however, a trailing P/E of 6.20x appears low for a commercial biotech with high gross margins, potentially reflecting market concerns over debt, competition, or future growth sustainability. Historical context for the stock's own valuation range is also unavailable, making it impossible to determine if the current P/E is near historical highs or lows, which limits the ability to assess whether the stock is priced for optimism or pessimism relative to its own trading history.
PE
6.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
5.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. The company's negative debt-to-equity ratio of -4.01 and negative ROE of -221.45% signal a capital structure crippled by past losses and leverage. While the current ratio of 2.06 shows adequate liquidity, the path to generating sufficient free cash flow to service debt and fund operations is critical and unproven. Revenue concentration risk is high, as the company's fate is tied almost entirely to the commercial success of ORLADEYO in the competitive HAE market.
Market & Competitive Risks include valuation compression. The stock's low trailing P/E of 6.20x may reflect deep-seated concerns rather than a bargain, and a re-rating to a higher multiple is not guaranteed. The beta of 0.69 suggests lower-than-typical biotech volatility, but this could increase if growth expectations falter. Competitive disruption from existing injectable therapies or new oral entrants poses a constant threat to market share and pricing power for ORLADEYO.
Worst-Case Scenario involves ORLADEYO sales growth stalling or decelerating sharply, leading to a cash flow crunch that makes the debt burden unsustainable. This could trigger a liquidity crisis, forced equity dilution at depressed prices, or restructuring. The realistic downside is significant, with the stock potentially retesting its 52-week low of $6.00, representing a loss of approximately -33% from the recent close of $9.02. The historical max drawdown of -44.24% provides a precedent for severe declines.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The unsustainable capital structure evidenced by a negative debt-to-equity of -4.01 and negative ROE of -221.45%. 2) Execution Risk: Revenue must hit analyst estimates of ~$1.3B to justify the forward valuation; any shortfall could crater the stock. 3) Competitive Risk: ORLADEYO operates in a competitive HAE market against entrenched injectable therapies. 4) Sentiment Risk: Low analyst coverage (3 analysts) and high short interest (short ratio 8.06) can exacerbate volatility.
The 12-month forecast is bifurcated with a base case target range of $9.00-$10.50 (50% probability), a bull case target of $11.31-$13.00 (30% probability), and a bear case target of $6.00-$7.50 (20% probability). The base case is most likely, assuming ORLADEYO revenue meets the consensus estimate of ~$1.30 billion and the company manages its debt without major issues. The forecast is highly dependent on quarterly execution and balance sheet developments.
BCRX sends mixed valuation signals. On a trailing basis, a P/E of 6.20x and a P/S of 1.87x appear undervalued for a profitable biotech with a 97.82% gross margin. However, the forward P/E of 11.25x indicates the market is pricing in significant future earnings growth. The valuation is likely fair relative to the company's high growth expectations and equally high financial risk, implying the market is cautiously optimistic but demanding a risk premium for the balance sheet concerns.
BCRX is a high-risk, high-potential-reward stock that may be a good buy only for investors with a high risk tolerance and a conviction in the commercial ramp of ORLADEYO. The trailing P/E of 6.20x appears cheap, and the stock has strong recent momentum. However, the significant debt burden (debt-to-equity of -4.01) and limited analyst coverage add substantial risk. It is not a good buy for conservative investors seeking stability or income.
BCRX is more suitable for a medium-to-long-term investment horizon (2-3 years minimum) for investors betting on the full commercial maturation of ORLADEYO and balance sheet repair. While the beta of 0.69 suggests lower volatility, the stock's price is highly sensitive to binary quarterly results. Short-term trading is risky due to the potential for sharp moves on news. The lack of a dividend also makes it purely a capital appreciation story, aligning with a longer-term growth holding period.